Q3 EPS Estimate for Unicycive Therapeutics Lifted by Analyst

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Equities research analysts at Noble Financial increased their Q3 2026 EPS estimates for shares of Unicycive Therapeutics in a report released on Thursday, August 13th. Noble Financial analyst R. Leboyer now forecasts that the company will post earnings of ($0.23) per share for the quarter, up from their previous estimate of ($0.35). The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.17) per share. Noble Financial also issued estimates for Unicycive Therapeutics’ Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($0.62) EPS, Q1 2027 earnings at $0.64 EPS and FY2027 earnings at $3.70 EPS.

A number of other brokerages also recently issued reports on UNCY. Benchmark decreased their price target on shares of Unicycive Therapeutics from $18.00 to $13.00 and set a “speculative buy” rating for the company in a research note on Wednesday, July 1st. Wall Street Zen upgraded shares of Unicycive Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Guggenheim reaffirmed a “buy” rating and set a $25.00 price objective (down from $37.00) on shares of Unicycive Therapeutics in a research report on Thursday. Weiss Ratings raised Unicycive Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 9th. Finally, B. Riley Financial restated a “buy” rating and issued a $20.00 price target (down from $22.00) on shares of Unicycive Therapeutics in a research note on Wednesday, August 12th. Five analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, Unicycive Therapeutics presently has an average rating of “Hold” and an average target price of $18.25.

Unicycive Therapeutics Stock Up 1.1%

Shares of UNCY stock opened at $5.57 on Monday. The firm has a 50 day moving average of $5.92 and a two-hundred day moving average of $6.63. The stock has a market capitalization of $155.12 million, a PE ratio of -3.18 and a beta of 1.79. Unicycive Therapeutics has a 52 week low of $3.71 and a 52 week high of $8.74.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.41.

Institutional Investors Weigh In On Unicycive Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP purchased a new position in Unicycive Therapeutics in the 1st quarter valued at approximately $940,000. Seven Fleet Capital Management LP purchased a new stake in Unicycive Therapeutics during the first quarter worth $367,000. Millennium Management LLC acquired a new stake in Unicycive Therapeutics in the fourth quarter valued at $5,856,000. Vivo Capital LLC increased its position in shares of Unicycive Therapeutics by 57.4% in the third quarter. Vivo Capital LLC now owns 1,789,916 shares of the company’s stock valued at $7,804,000 after buying an additional 652,901 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new position in shares of Unicycive Therapeutics during the 3rd quarter worth $512,000. Institutional investors and hedge funds own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.